MD Anderson Cancer Center chief medical executive Stephen Hahn has been confirmed by the U.S. Senate as FDA commissioner. On December 12, the Senate voted 72-18 to confirm Dr. Hahn. He will become the 24th FDA commissioner, succeeding Scott Gottlieb.
He has served MD Anderson Cancer Center as Division Head Department Chair. Prior to his role in Texas, he served a number of leading positions in oncology at the University of Pennsylvania, School of Medicine for nine years from 2005 to 2014.
Upon graduating medical school, he served as a provider radiation oncologist in Santa Rosa, California. He then moved to public service, serving as commander in the U.S. Public Health Service Commissioned Corp while working at the National Cancer Institute (NCI) from 1993-1999 and served as chief of NCI’s Prostate Cancer Clinic in the Clinical Pharmacology Branch. Thereafter, Dr. Hahn joined the University of Pennsylvania.
Dr. Hahn has been a long-standing member of the American Society of Clinical Oncology (ASCO), the Radiation Research Society, the American Society of Photobiology, the American Association for Cancer Research as well as other groups.
What does the Commissioner of the FDA do?
Appointed by the President of the United State with the advice and consent of the Senate, the Commissioner reports to the Secretary of Health and Human Services. Hahn replaces acting commissioner Admiral Brett Giroir. The Commissioner has a big job. They have many different departments report in as they lead the entire organization, representing approximately 17,500 employees.